Recognizing and correcting failures in glioblastoma treatment

Cancer Investigation

Volumn 32, Issue 6, 2014, Pages 299-302

  Shah, Ashish H ^a   Graham, Regina ^a   Bregy, Amade ^a   Thambuswamy, Michael ^a   Komotar, Ricardo J ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Editorial; Glioblastoma; Treatment

Indexed keywords

BEVACIZUMAB; DENDRITIC CELL VACCINE; EVEROLIMUS;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STEM CELL; CANCER SURVIVAL; CELL HETEROGENEITY; GLIOBLASTOMA; HUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; TREATMENT FAILURE;

EDITORIAL; GLIOBLASTOMA; TREATMENT;

BRAIN NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS;

EID: 84902170312     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2014.909827     Document Type: Article

References (34)

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10(5):459-466.
2. Coffey RJ, Lunsford LD, Taylor FH. Survival after stereotactic biopsy of malignant gliomas. Neurosurgery 1988;22(3):465-473.
3. Ma X, Lv Y, Liu J, Wang D, Huang Q, Wang X, Li G, Xu S, Li X. Survival analysis of 205 patients with glioblastomamultiforme: clinical characteristics, treatment and prognosis in China. J Clin Neurosci 2009;16(12):1595-1598.
4. Salvati M, Pichierri A, Piccirilli M, Floriana Brunetto GM, D'Elia A, Artizzu S, Santoro F, Arcella A, Giangaspero F, Frati A, Simione L, Santoro A. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients. J Neurosurg 2012;117(2):204-211.
5. Cao VT, Jung TY, Jung S, Jin SG,Moon KS, KimIY, Kang SS, Park CS, Lee KH, Chae HJ. The correlation and prognostic significance ofMGMT promoter methylation andMGMT protein in glioblastomas. Neurosurgery 2009;65(5):866-875; discussion 875.
6. De Bonis P, Anile C, Pompucci A, Fiorentino A, Balducci M, Chiesa S, Maira G, Mangiola A. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma.ActaNeurochir (Wien) 2012;154(8):1371-1378.
7. Burkhardt JK, Riina HA, Shin BJ, Moliterno JA, Hofstetter CP, Boockvar JA. Intra-arterial chemotherapy for malignant gliomas: a critical analysis. Interv Neuroradiol 2011;17(3):286-295.
8. Bregy A, Shah AH, DiazMV, Pierce HE, Ames PL, Diaz D, Komotar RJ. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert Rev AnticancerTher 2013;13(12):1453-1461.
9. Hainsworth JD, Shih KC, Shepard GC, Tillinghast GW, Brinker BT, Spigel DR. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/ everolimus as first-line treatment for patients with glioblastoma. Clin Adv Hematol Oncol 2012;10(4):240-246.
10. Cho DY, Yang WK, Lee HC, Hsu DM, Lin HL, Lin SZ, Chen CC, Harn HJ, Liu CL, Lee WY, Ho LH. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial. World Neurosurg 2012;77(5-6):736-744.
11. Phuphanich S,Wheeler CJ, Rudnick JD,MazerM,Wang H, Nuno MA, Richardson JE, Fan X, Ji J, Chu RM, Bender JG, Hawkins ES, Patil CG, Black KL, Yu JS. Phase I trial of a multi-epitopepulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother 2013;62(1):125-135.
12. Bregy A, Wong TM, Shah AH, Goldberg JM, Komotar RJ. Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme. Cancer Treat Rev 2013;39(8):891-907.
13. Shah AH, Bregy A, Heros DO, Komotar RJ, Goldberg J. Dendritic Cell Vaccine for recurrent high grade gliomas in pediatric and adult subjects: Clinical Trial Protocol. Neurosurgery 2013.
14. Dunn GP, Fecci PE, Curry WT. Cancer immunoediting in malignant glioma. Neurosurgery 2012;71(2):201-222; discussion 222-223.
15. Kim HS, Woolard K, Lai C, Bauer PO, Maric D, Song H, Li A, Kotliarova S, Zhang W, Fine HA. Gliomagenesis arising from Pten-and Ink4a/Arf-deficient neural progenitor cells is mediated by the p53-Fbxw7/Cdc4 pathway, which controls c-Myc. Cancer Res 2012;72(22):6065-6075.
16. Momota H, Narita Y,Matsushita Y, Miyakita Y, Shibui S. p53 abnormality and tumor invasion in patients withmalignant astrocytoma. Brain Tumor Pathol 2010;27(2):95-101.
17. Goldhoff P, Clarke J, Smirnov I, Berger MS, Prados MD, James CD, Perry A, Phillips JJ. Clinical stratification of glioblastoma based on alterations in retinoblastoma tumor suppressor protein (RB1) and association with the proneural subtype. J Neuropathol Exp Neurol 2012;71(1):83-89.
18. de Almeida Sassi F, Lunardi BrunettoA, SchwartsmannG, Roesler R, Abujamra AL. Glioma revisited: from neurogenesis and cancer stem cells to the epigenetic regulation of the niche. J Oncol 2012;2012:537-861.
19. Chen J, Li Y, Yu TS,McKay RM, Burns DK, Kernie SG, Parada LF. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012;488(7412):522-526.
20. Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, Stassi G, Martini M, Maira G, Larocca LM, De Maria R. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res 2008;14(24): 8205-8212.
21. LiuG, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006;5:67.
22. Cheng JX, Liu BL, Zhang X. How powerful is CD133 as a cancer stem cell marker in brain tumors? Cancer Treat Rev 2009;35(5):403-408.
23. Kreth S,Thon N, Kreth FW. Epigenetics in human gliomas. Cancer Lett 2012;342(2):185-192.
24. Martinez R, Schackert G. Epigenetic aberrations in malignant gliomas: an open door leading to better understanding and treatment. Epigenetics 2007;2(3):147-150.
25. Mack GS. To selectivity and beyond. Nature Biotechnology 2010;28(12):1259-1266.
26. Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, ForrestWF, Pujara K, Carrillo JA, Pandita A, Ellingson BM, Bowers CW, Soriano RH, Schmidt NO, Mohan S, Yong WH, Seshagiri S, Modrusan Z, Jiang Z, Aldape KD,Mischel PS, Liau LM, Escovedo CJ, Chen W, Nghiemphu PL, James CD, Prados MD, Westphal M, Lamszus K, Cloughesy T, Phillips HS. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 2011;29(34):4482-4490.
27. KimY, KimKH, Lee J, Lee YA,KimM, Lee SJ, ParkK, YangH, Jin J, JooKM, Lee J,NamDH.Wnt activation is implicated in glioblastoma radioresistance. Lab Invest 2011;92(3):466-473.
28. Weller M, Wick W, Hegi ME, Stupp R, Tabatabai G. Should biomarkers be used to design personalized medicine for the treatment of glioblastoma? Future Oncol 2010;6(9):1407-1414.
29. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, Hegi ME. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 2010;6(1):39-51.
30. Toedt G, Barbus S, Wolter M, Felsberg J, Tews B, Blond F, Sabel MC, Hofmann S, Becker N, Hartmann C, Ohgaki H, von Deimling A, Wiestler OD, Hahn M, Lichter P, Reifenberger G, Radlwimmer B.Molecular signatures classify astrocytic gliomas by IDH1 mutation status. Int J Cancer 2011;128(5):1095-1103.
31. Srividya MR, Thota B, Arivazhagan A, Thennarasu K, Balasubramaniam A, Chandramouli BA, Hegde AS, Santosh V. Agedependent prognostic effects of EGFR/p53 alterations in glioblastoma: study on a prospective cohort of 140 uniformly treated adult patients. J Clin Pathol 2010;63(8):687-691.
32. Idbaih A, Omuro A, Ducray F, Hoang-Xuan K. Molecular genetic markers as predictors of response to chemotherapy in gliomas. Curr Opin Oncol 2007;19(6):606-611.
33. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455(7216): 1061-1068.
34. Schonberg DL, Bao S, Rich JN. Genomics informs glioblastoma biology. Nat Genet 2013;45(10):1105-1107.